The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report
Case Reports in Hematology · 2026-01 · 2026 (1)
DOI: 10.1155/crh/3903470 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Hematology, online erschienen am 13.05.2026. Verfasst von Roudy Issa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Immunology, Notre Dame des Secours University Hospital, Jbeil, Lebanon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic (VEXAS) syndrome is a rare, adult‐onset autoinflammatory disease that has only been described since late 2020. Given the rarity of the disease and the absence of established treatment guidelines, management remains challenging and largely based on clinical experience and case reports. Case presentation This paper reports the first documented case of VEXAS syndrome in Lebanon. A 73‐year‐old man presented with fever, severe asthenia, erythematous skin lesions, and anemia, initially diagnosed as giant cell arteritis. Following a diagnosis of VEXAS syndrome, he was treated with corticosteroids and methotrexate but developed refractory anemia and required erythropoietin therapy. Tocilizumab was introduced to manage inflammation, but the patient’s condition remained challenging due to corticosteroid dependence and myelodysplastic syndrome (MDS). Given the patient’s comorbidities and intermediate‐risk MDS, azacitidine was initiated as a therapeutic option. Despite initial neutropenia and infections, adjustments to the azacitidine regimen led to significant clinical and hematologic improvements. The patient achieved complete remission, became transfusion‐independent, and maintained stable hemoglobin levels.
Conclusion
This case highlights the efficacy of azacitidine in managing VEXAS syndrome with MDS, particularly among patients ineligible for hematopoietic stem cell transplantation, offering a potential pathway to sustained remission and reduced corticosteroid dependence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Immunology, Notre Dame des Secours University Hospital, Jbeil, Lebanon.
- Department of Gastroenterology and Hepatology, Notre Dame des Secours University Hospital, Jbeil, Lebanon.
- Department of Internal Medicine, Sorbonne University, AP-HP Tenon, Paris, France, sorbonne-universites.fr.
- Department of Biological Hematology, Paris Cite University, AP-HP Cochin, Paris, France.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
- Department of Hematology/Oncology, Notre Dame des Secours University Hospital, Jbeil, Lebanon.
ORCID-Profile: Roudy Issa, Bassem Akiki, Sophie Georgin-Lavialle, Olivier Kosmider, Danielle Hammond, Marcel Massoud, Elissar Dagher
Zitieren
APA
Issa, R., Akiki, B., Georgin-Lavialle, S., Kosmider, O., Hammond, D., Massoud, M., Najjar, V., & Dagher, E. (2026). The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/3903470
Vancouver
Issa R, Akiki B, Georgin-Lavialle S, Kosmider O, Hammond D, Massoud M, et al. The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/3903470
BibTeX
@article{Issa2026,
author = {Issa, Roudy and Akiki, Bassem and Georgin-Lavialle, Sophie and Kosmider, Olivier and Hammond, Danielle and Massoud, Marcel and Najjar, Vicky and Dagher, Elissar},
title = {The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option—Case Report},
journal = {Case Reports in Hematology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crh/3903470}
}
EUVIMED